Perspectives on Placebo: The Psychology of Neurofeedback

  • Kirtley E. Thornton neuroscience center
Keywords: neurotherapy, EEG biofeedback, placebo, alpha, endorphins, dopamine


The application of operant conditioning with EEG variables to produce changes in behavior has been gaining increasing interest in research and application areas.  However, the methodology has come under scrutiny and criticism for its potential placebo effects.  This article will examine those issues from the traditional methodologies of demonstrating effectiveness (control group, sham treatments) as well as examine the possible biochemical and electrophysiological effects of a placebo response.  Specifically, the role of endorphins and dopamine and their relationship to the alpha and beta frequency in the placebo response will be examined.  The research addressing the diffusion tensor imaging (DTI) and functional magnetic resonance imaging (fMRI) correlates of the intervention will be examined.


Amanzio, M., & Benedetti, F. (1999). Neuropharmacological dissection of placebo analgesia: Expectation-activated opioid systems versus conditioning-activated specific subsystems. The Journal of Neuroscience, 19(1), 484–494.

Arruda, J. E., Zhang, H., Amoss, R. T., Coburn, K. L., & Aue, W. R. (2009). Rhythmic oscillations in quantitative EEG measured during a continuous performance task. Applied Psychophysiology and Biofeedback, 34(1), 7–16.

Auckland District Health Board (ADHB). (2018). Newborn Services Drug Protocol. Dopamine hydrochloride. Retrieved from /DopaminePharmacology.htm

Banich, M. T., Milham, M. P., Atchley, R., Cohen, N. J., Webb, A., Wszalek, T., … Magin, R. (2000). fMRI studies of Stroop tasks reveal unique roles of anterior and posterior brain systems in attentional selection. Journal of Cognitive Neuroscience, 12(6), 988–1000.

Barkley, R. A. (1998). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (2nd ed.). New York, NY: Guilford Press.

Barry, R. J., Clarke, A. R., & Johnstone, S. J. (2003). A review of electrophysiology in attention-deficit/hyperactivity disorder: I. Qualitative and quantitative electroencephalography. Clinical Neurophysiology, 114(2), 171–183.

Beecher, H. K. (1955). The powerful placebo. Journal of the American Medical Association, 159(17), 1602–1606.

Benedetti, F., Colloca, L., Torre, E., Lanotte, M., Melcarne, A., Pesare, M., … Lopiano, L. (2004). Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nature Neuroscience, 7(6), 587–588.

Bresnahan, S. M., Barry, R. J., Clarke, A. R., & Johnstone, S. J. (2006). Quantitative EEG analysis in dexamphetamine-responsive adults with attention-deficit/hyperactivity disorder. Psychiatry Research, 141(2), 151–159. /10.1016/j.psychres.2005.09.002

Buchsbaum, M. S., Hazlett, E., Sicotte, N., Stein, M., Wu, J., & Zetin, M. (1985). Topographic EEG changes with benzodiazepine administration in generalized anxiety disorder. Biological Psychiatry, 20(8), 832–842.

Bush, G., Frazier, J. A., Rauch, S. L., Seidman, L. J., Whalen, P. J., Jenike, M. A., … Biederman, J. (1999). Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop, Biological Psychiatry, 45(12), 1542–1552

Chabot, R. J., & Serfontein, G., (1996). Quantitative electroencephalographic profiles of children with attention deficit disorder. Biological Psychiatry, 40(10), 951–963.

Cheon, E.-J., Koo, B.-H., & Choi, J.-H. (2016). The efficacy of neurofeedback in patients with major depressive disorder: An open labeled prospective study. Applied Psychophysiology and Biofeedback, 41(1), 103–110.

Cherry, K. (2018, November 14). How the Placebo Effect Works in Psychology. Retrieved from /what-is-the-placebo-effect-2795466

Clarke, A. R., Barry, R. J., McCarthy, R., Selikowitz, M., & Johnstone, S. J. (2007). Effects of stimulant medications on the EEG of girls with attention-deficit/hyperactivity disorder. Clinical Neurophysiology, 118(12), 2700–2708.

Cowan, J. D., & Albers, S. A. (2009). Manual for the peak brain happiness trainer: Exited happiness and Neureka! Protocols. Goshen, KY: Peak Achievement Training.

Cowan, J. D., & Sokhadze, E. (2011). Prefrontal gamma neurofeedback improves emotional state and cognitive function. Applied Psychophysiology and Biofeedback, 36, S220.

Cowan, J., & Sokhadze, E. (2010, September 29–October 3). Happiness specifically increases a clarified 40 Hz EEG rhythm used for neurofeedback. Presented at the 18th International Society Neurofeedback Research Annual Conference, Denver, CO.

Crabbe, J. B., & Dishman, R. K. (2004). Brain electrocortical activity during and after exercise: A quantitative synthesis. Psychophysiology, 41(4), 563–574.

Dalayeun, J. F., Norès, J. M., Bergal, S. (1993). Physiology of beta-endorphins. A close-up view and a review of the literature. Biomedicine & Pharmacotherapy, 47(8), 311–320.

de la Fuente-Fernández, R., Ruth, T. J., Sossi, V., Schulzer, M., Calne, D. B., & Stoessl, A. J. (2001). Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease. Science, 293(5532), 1164–1166.

Eippert, F., Bingel, U., Schoell, E. D., Yacubian, J., Klinger, R., Lorenz, J., & Büchel, C. (2009). Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron, 63(4), 533–543.

Ernst, M., Zametkin, A. J., Matochik, J. A., Liebenauer, L. Fitzgerald, G. A., & Cohen, R. M. (1994). Effects of intravenous dextroamphetamine on brain metabolism in adults with attention-deficit/hyperactivity disorder (ADHD): Preliminary findings. Psychopharmacology Bulletin, 30(20), 219–225.

Feinberg, C. (2013, January–February). The placebo phenomenon. An ingenious researcher finds the real ingredients of “fake” medicine. Harvard Magazine, 115(3), 36–39.

Foley, K. M., Kourides, I. A., Inturrisi, C. E., Kaiko, R. F., Zaroulis, C. G., Posner, J. B., … Li, C. H. (1979). β-Endorphin: Analgesic and hormonal effects in humans. Proceedings of the National Academy of Sciences of the United States of America, 76(10), 5377–5381.

Furmark, T., Appel, L., Henningsson, S., Åhs, F., Faria, V., Linnman, C., … Fredrikson, M. (2008). A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. The Journal of Neuroscience, 28(49), 13066–13074.

Gabrielli, W. F., Mednick, S. A., Volavka, J., Pollock, V. E., Schulsinger, F. & Itil, T. M. (1982). Electroencephalograms in children of alcoholic fathers. Psychophysiology, 19(4), 404-407.

Gani, C., Birbaumer, N., & Strehl, U. (2008). Long term effects after feedback of slow cortical potentials and of theta-beta-amplitudes in children with attention deficit/hyperactivity disorder (ADHD). International Journal of Bioelectromagnetics, 10(4), 209–232.

Gevensleben, H., Holl, B., Albrecht, B., Schlamp, D., Kratz, O., Studer, P., … Heinrich, H. (2009). Distinct EEG effects related to neurofeedback training in children with ADHD: A randomized controlled trial. International Journal of Psychophysiology, 74(2), 149–157.

Gevensleben, H., Holl, B., Albrecht, B., Schlamp, D., Kratz, O., Studer, P., … Heinrich, H. (2010). Neurofeedback training in children with ADHD: 6-month follow-up of a randomised controlled trial. European Child & Adolescent Psychiatry, 19(9), 715–724.

Gevensleben, H., Holl, B., Albrecht, B., Vogel, C., Schlamp, D., Kratz, O., … Heinrich, H. (2009). Is neurofeedback an efficacious treatment for ADHD? A randomized controlled clinical trial. Journal of Child Psychology and Psychiatry, 50(7), 780–789.

Ghaziri, J., Tucholka, A., Larue, V., Blanchette-Sylvestre, M., Reyburn, G., Gilbert, G., … Beauregard, M. (2013). Neurofeedback training induces changes in white and gray matter. Clinical EEG and Neuroscience, 44(4), 265–272.

Gracely, R. H., Dubner, R., Wolskee, P. J., & Deeter, W. R. (1983). Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature, 306(5940), 264–265.

Grevert, P., Albert, L. H., & Goldstein, A. (1983). Partial antagonism of placebo analgesia by naloxone. Pain, 16(1), 129–143.

Grin-Yatsenko, V. A., Othmer, S., Ponomarev, V. A., Evdokimov, S. A., Konoplev, Y. Y., & Kropotov, J. D. (2018) Infra-low frequency neurofeedback in depression: Three case studies. NeuroRegulation, 5(1), 30–42.

Gruzelier, J. H. (2014). EEG-neurofeedback for optimising performance. III: A review of methodological and theoretical considerations. Neuroscience & Biobehavioral Reviews, 44, 159 –182.

Gunkelman, J. (2009, December 23). Drug exposure and EEG/qEEG findings. Retrieved from Drug exposure and EEG.pdf

Gurnee, R. (2003). QEEG subtypes of anxiety. Presented at the International Society for Neurofeedback and Research 11th Annual Conference, Houston, TX.

Hall, K. T., Lembo. A. J., Kirsch. I., Ziogas, D. C., Douaiher, J., Jensen, K. B., … Kaptchuk, T. J. (2012). Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS ONE, 7(10), e48135.

Hall, K. T., Loscalzo, J., & Kaptchuk, T. J. (2015). Genetics and the placebo effect: The placebome. Trends in Molecular Medicine, 21(5), 285–294.

Hamilton, L. S., Levitt, J. G., O’Neil, J., Alger, J. R., Luders, E., Phillips, O. R., ... Narr, K. L. (2008). Reduced white matter integrity in attention-deficit hyperactivity disorder. Neuroreport, 19(17), 1705–1708.

Hammond, D. C. (2005). Neurofeedback with anxiety and affective disorders. Child and Adolescent Psychiatric Clinics of North America, 14(1), 105–123.

Heller, W., Nitschke, J. B., Etienne, M. A., & Miller, G. A. (1997). Patterns of regional brain activity differentiate types of anxiety. Journal of Abnormal Psychology, 106(3), 376–385.

Hróbjartsson, A., & Gøtzsche, P. A. (2010). Placebo interventions for all clinical conditions. Cochrane Database of Systematic Reviews, 1.

Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., … Lembo, A. J. (2010). Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS ONE, 5(12), e15591.

Kong, J., Gollub, R. L., Rosman, I. S., Webb, J. M., Vangel, M. G., Kirsch, I., & Kaptchuk, T. J. (2006). Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. The Journal of Neuroscience, 26(2), 381–388. /JNEUROSCI.3556-05.2006

Konrad, A., Dielentheis, T. F., Masri, D. E., Dellani, P. R., Stoeter, P., Vucurevic, G., & Winterer, G. (2012). White matter abnormalities and their impact on attentional performance in adult attention-deficit/hyperactivity disorder. European Archives of Psychiatry and Clinical Neuroscience, 262(4), 351–360.

Leins, U., Goth, G., Hinterberger, T., Klinger, C., Rumpf, N., & Strehl, U. (2007). Neurofeedback for children with ADHD: A comparison of SCP and theta-beta protocols. Applied Psychophysiology and Biofeedback, 32(2), 73–88.

Leuchter, A. F., Cook, I. A., Witte, E. A., Morgan, M., & Abrams, M. (2002). Changes in brain function of depressed subjects during treatment with placebo. The American Journal of Psychiatry, 159(1), 122–129.

Lévesque, J., Beauregard, M., & Mensour, B. (2006). Effect of neurofeedback training on the neural substrates of selective attention in children with attention-deficit/hyperactivity disorder: A functional magnetic resonance imaging study. Neuroscience Letters, 394(3), 216–221.

Levine, J. D., Gordon, N. C., Jones, R. T., & Fields, H. L. (1978). The narcotic antagonist naloxone enhances clinical pain. Nature, 272, 826–827.

Lipman, J. J., Miller, B. E., Mays, K. S., Miller, M. N., North, W. C., & Byrne, W. L. (1990). Peak B endorphin concentration in cerebrospinal fluid: reduced in chronic pain patients and increased during the placebo response. Psychopharmacology, 102(1), 112–116.

Lubar, J. F., Swartwood, M. O., Swartwood, J. N., & Timmermann, D. L. (1996). Quantitative EEG and auditory event-related potentials in the evaluation of attention-deficit/hyperactivity disorder: Effects of methylphenidate and implications for neurofeedback training. [Monograph: Assessment of Attention-Deficit/Hyperactivity Disorders]. Journal of Psychoeducational Assessment, 143–204.

Matochik, J. A., Liebenauer, L. L., King, A. C., Szymanski, H. V., Cohen, R. M., & Zametkin, A. J. (1994). Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment. American Journal of Psychiatry, 151(5), 658–664.

Matsuura, M., Okubo, Y., Toru, M., Kojima, T., He, Y., Hou, Y., … Lee, C. K. (1993). A cross-national EEG study of children with emotional and behavioral problems: A WHO collaborative study in the Western Pacific Region. Biological Psychiatry, 34(1–2), 59–65.

Mimasa, F., Hayashi, T., Shibata, M., Yoshitake, Y., Nishijima, Y., & Moritani, T. (1996). Movement of electroroencephalogram and plasm β-endorphin in the aerobic exercise. Japanese Journal of Physical Fitness and Sports Medicine, 45(5), 519–526.

Molteni, E., Bianchi, A. M., Butti, M., Reni, G., & Zucca, C., (2007). Analysis of the dynamical behaviour of the EEG rhythms during a test of sustained attention. Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 1298–1301.

Monastra, V. J., Monastra, D. M., & George, S. (2002). The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. Applied Psychophysiology and Biofeedback, 27(4), 231–249.

Nestler, E. J., Hyman, S. E., & Malenka, R. C., (2009). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed., p. 321). New York, NY: McGraw-Hill Medical.

Niogi, S., Mukherjee, P., Ghajar, J., & McCandliss, B. D. (2010). Individual differences in distinct components of attention are linked to anatomical variations in distinct white matter tracts. Frontiers in Neuroanatomy, 4, 2.

Pavuluri, M. N., Yang, S., Kamineni, K., Passarotti, A. M., Srinivasan, G., Harral, E. M., … Zhou, X. J. (2009). Diffusion tensor imaging study of white matter fiber tracts in pediatric bipolar disorder and attention-deficit/hyperactivity disorder. Biological Psychiatry, 65(7), 586¬–593.

Peniston, E. G., & Kulkosky, P. J. (1989). Alpha-theta brainwave training and beta-endorphin levels in alcoholics. Alcoholism, Clinical & Experimental Research, 13(2), 271–279.

Petrovic, P., Dietrich, T., Fransson, P., Andersson, J., Carlsson, K., & Ingvar, M. (2005). Placebo in emotional processing—induced expectations of anxiety relief activate a generalized modulatory network. Neuron, 46(6), 957–969.

Petrovic, P., Kalso, E., Petersson, K. M., & Ingvar, M. (2002). Placebo and opioid analgesia—imaging a shared neuronal network. Science, 295(5560), 1737–1740.

Pfefferbaum, A., Berger, P. A., Elliot, G. R., Tinklenberg, J. R., Kopell, B. S., Barchas, J. D., & Li, C. H. (1979). Human EEG response to beta-endorphin. Psychiatry Research, 1(1), 83–88.

Qiu, M.-G., Ye, Z., Li, Q.-Y., Liu, G.-J., Xie, B., & Wang, J. (2011). Changes of brain structure and function in ADHD children. Brain Topography, 24(3-4), 243–252.

Raymond, J., Varney, C., Parkinson, L. A., & Gruzelier, J. H. (2005). The effects of alpha/theta neurofeedback on personality and mood. Cognitive Brain Research, 23(2–3), 287–292.

Rossi, E. L. (1986). The psychobiology of mind-body healing: New concepts of therapeutic hypnosis (Rev. ed.). New York, NY: W. W. Norton & Company, Inc.

Saletu, B., Anderer, P., Saletu-Zyhlarz, G. M., Arnold, O., & Pascual-Marqui, R. D. (2002). Classification and evaluation of the pharmacodynamics of psychotropic drugs by single-lead pharmaco-EEG, EEG mapping and tomography (LORETA). Methods and Findings in Experimental and Clinical Pharmacology, 24(Suppl. C), 97–120.

Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K. (2008). Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Archives of General Psychiatry, 65(2), 220–231.

Scott, W. C., Kaiser, D., Othmer, S., & Sideroff, S. I. (2005). Effects of an EEG biofeedback protocol on a mixed substance abusing population. The American Journal of Drug and Alcohol Abuse, 31(3), 455–469.

Sherlin, L., Arns, M. Lubar, J., & Sokhadze, E. (2010). A position paper on neurofeedback for treatment of ADHD. Journal of Neurotherapy, 14(2), 66–78.

Skinner, B. F. (1938). The behavior of organisms: An experimental analysis. New York, NY: Appleton-Century-Crofts, Inc.

Snyder, S. M., & Hall, J. R. (2006). A meta-analysis of quantitative EEG power associated with attention-deficit/hyperactivity disorder. Journal of Clinical Neurophysiology, 23(5), 441–456.

Sokhadze, E. M., & Daniels, R. (2016). Effects of prefrontal 40 Hz-centered EEG band neurofeedback on emotional state and cognitive functions in adolescents. Adolescent Psychiatry, 6(2), 116–129.

Sokhadze, T. M., Cannon, R. L., & Trudeau, D. L. (2008). EEG biofeedback as a treatment for substance use disorders: Review, rating of efficacy, and recommendations for further research. Applied Psychophysiology and Biofeedback, 33(1), 1–28.

Staddon, J. E. R., & Cerutti, D. T. (2003). Operant conditioning. Annual Review of Psychology, 54, 115–144.

Thibault, R. T., & Raz, A. (2017). The psychology of neurofeedback: Clinical intervention even if applied placebo. American Psychologist, 72(7), 679–688.

Thornton, K. E. (2006). No child left behind goals (and more) are attainable with neurocognitive interventions (Vol. 1). North Charleston, SC: Booksurge Press.

Thornton, K. (2016). How the cognitive brain works: The quantitative EEG and cognition. Clover, SC: Kirtley Thornton. Printed by Create Space.

Thornton, K. E., & Carmody, D. P. (2005). EEG biofeedback for reading disabilities and traumatic brain injuries. Child and Adolescent Psychiatric Clinics of North America, 14(1), 137–162.

Thornton, K. E., & Carmody, D. P. (2008). Efficacy of traumatic brain injury rehabilitation: interventions of qEEG-guided biofeedback, computers, strategies, and medications. Applied Psychophysiology and Biofeedback, 33(2), 101–124.

Thornton, K. E., & Carmody, D. P. (2013). The relation between memory improvement and qEEG changes in three clinical groups as a result of EEG biofeedback treatment. Journal of Neurotherapy, 17(2), 116–132.

van Ewijk, H., Heslenfeld, D. J., Zwiers, M. P., Buitelaar, J. K., & Oosterlaan, J. (2012). Diffusion tensor imaging in attention deficit/hyperactivity disorder: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 36(4), 1093–1106.

Volavka, J., James, B., Reker, D., & Cho, D. (1979). Electroencephalographic and other effects of naloxone in normal men. Life Sciences, 25(14), 1267–1272.

Wager, T. D., Rilling, J. K., Smith, E. E., Sokolik, A., Casey, K. L., Davidson, R. J., … Cohen, J. D. (2004). Placebo-induced changes in fMRI in the anticipation and experience of pain. Science, 303(5661), 1162–1167.

Wager, T. D., Scott, D. J., & Zubieta, J. K. (2007). Placebo effects on human mu-opioid activity during pain. Proceedings of the National Academy of Sciences of the United States of America, 104(26), 11056–11061.

Walker, J. E. (2009). Anxiety associated with post traumatic stress disorder—The role of quantitative electroencephalograph in diagnosis and in guiding neurofeedback training to remediate the anxiety. Biofeedback, 37(2), 67–70.

Wang, S.-Y., Lin, I.-M., Peper, E., Chen, Y.-T., Yeh, Y.-C., … Chu, C. (2016). The efficacy of neurofeedback among patients with major depressive disorder: Preliminary study. NeuroRegulation, 3(3), 127–134.

Wechsler, M. E., Kelley, J. M., & Kaptchuk, T. J. (2011). Placebos and other interventions in asthma. The New England Journal of Medicine, 365(15), 1447.

World Research Foundation (WRF) Staff. (n.d.) The power of mind and the promise of placebo. Retrieved from

Zubieta, J.-K., Bueller, J. A., Jackson, L. R., Scott, D. J., Xu, Y., Koeppe, R. A., … Stohler, C. S. (2005). Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. The Journal of Neuroscience, 25(34), 7754–7762.

Zubieta, J.-K., & Stohler, C. S. (2009). Neurobiological mechanisms of placebo responses. Annals of the New York Academy of Sciences, 1156(1), 198–210. /10.1111/j.1749-6632.2009.04424.x